drugset / Trial / NCT03425474

Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy

NCT03425474

Phase 3 Completed 378 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupSingle-blindOther

Summary

The purpose of this study is to evaluate the safety and efficacy of the sedation for Remimazolam or Propofol in patients undergoing diagnostic upper GI endoscopy.

Timeline

Start
2017-09-01
Primary completion
2017-11-10
Completion
2017-11-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 1.5 mg/kg
Subject Remimazolam Small molecule 5 mg

Indications

No indication recorded.